Abstract
BackgroundIL-2 and IL-12 synergistically trigger the stimulation and proliferation of T and NK cells to mediate anti-tumor immunity. Although aldesleukin, a high-dose IL-2 intravenous (IV) infusion regimen, has been approved...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have